Citations (104)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
V. Parrino, G. De Marco, R. Minutoli, G. Lo Paro, A. Giannetto, T. Cappello, L. M. De Plano, S. Cecchini & F. Fazio. (2021) Effects of pesticides on Chelon labrosus (Risso, 1827) evaluated by enzymatic activities along the north eastern Sicilian coastlines (Italy). The European Zoological Journal 88:1, pages 540-548.
Read now
Read now
E. S. Castro-Silva, M. Bello, M. Hernández-Rodríguez, J. Correa-Basurto, J. I. Murillo-Álvarez, M. C. Rosales-Hernández & M. Muñoz-Ochoa. (2019) In vitro and in silico evaluation of fucosterol from Sargassum horridum as potential human acetylcholinesterase inhibitor. Journal of Biomolecular Structure and Dynamics 37:12, pages 3259-3268.
Read now
Read now
Li Zhou, Sha Tan, Yi-long Shan, Yu-ge Wang, Wei Cai, Xue-hong Huang, Xi-yuan Liao, Hai-yan Li, Lei Zhang, Bing-jun Zhang & Zheng-qi Lu. (2016) Baicalein improves behavioral dysfunction induced by Alzheimer’s disease in rats. Neuropsychiatric Disease and Treatment 12, pages 3145-3152.
Read now
Read now
Eva Horáková, Pavel Drabina, Břetislav Brož, Šárka Štěpánková, Katarína Vorčáková, Karel Královec, Radim Havelek & Miloš Sedlák. (2016) Synthesis, characterization and in vitro evaluation of substituted N-(2-phenylcyclopropyl)carbamates as acetyl- and butyrylcholinesterase inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry 31:sup3, pages 173-179.
Read now
Read now
Filip Zemek, Lucie Drtinova, Eugenie Nepovimova, Vendula Sepsova, Jan Korabecny, Jiri Klimes & Kamil Kuca. (2014) Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine. Expert Opinion on Drug Safety 13:6, pages 759-774.
Read now
Read now
Gabriel C Léger & Fadi Massoud. (2013) Novel disease-modifying therapeutics for the treatment of Alzheimer’s disease. Expert Review of Clinical Pharmacology 6:4, pages 423-442.
Read now
Read now
Articles from other publishers (98)
Rubina Munir, Sumera Zaib, Muhammad Zia-ur-Rehman, Nadia Hussain, Faryal Chaudhry, Muhammad Tayyab Younas, Fatima Tuz Zahra, Zainab Tajammul, Noman Javid, Ayed A. Dera, Hanan A. Ogaly & Imtiaz Khan. (2023) Ultrasound-Assisted Synthesis of Piperidinyl-Quinoline Acylhydrazones as New Anti-Alzheimer’s Agents: Assessment of Cholinesterase Inhibitory Profile, Molecular Docking Analysis, and Drug-like Properties. Molecules 28:5, pages 2131.
Crossref
Crossref
Denisa Claudia Miculas, Paul Andrei Negru, Simona Gabriela Bungau, Tapan Behl, Syed Shams ul Hassan & Delia Mirela Tit. (2022) Pharmacotherapy Evolution in Alzheimer’s Disease: Current Framework and Relevant Directions. Cells 12:1, pages 131.
Crossref
Crossref
Siew Lee Cheong, Jian Kai Tiew, Yi Hang Fong, How Wan Leong, Yew Mun Chan, Zhi Ling Chan & Ethan Wei Jie Kong. (2022) Current Pharmacotherapy and Multi-Target Approaches for Alzheimer’s Disease. Pharmaceuticals 15:12, pages 1560.
Crossref
Crossref
Kun Bu, Devashru Patel, Robert Morris, Weiru Han, Gibret Umeukeje, Tianrui Zhu & Feng Cheng. (2022) Dysphagia Risk in Patients Prescribed Rivastigmine: A Systematic Analysis of FDA Adverse Event Reporting System. Journal of Alzheimer's Disease 89:2, pages 721-731.
Crossref
Crossref
Miguel Pinto, Vera Silva, Sandra Barreiro, Renata Silva, Fernando Remião, Fernanda Borges & Carlos Fernandes. (2022) Brain drug delivery and neurodegenerative diseases: Polymeric PLGA-based nanoparticles as a forefront platform. Ageing Research Reviews 79, pages 101658.
Crossref
Crossref
Gabriel Rodrigues Coutinho Pereira, Lucas Machado Gonçalves, Bárbara de Azevedo Abrahim‐Vieira & Joelma Freire De Mesquita. (2022) In silico analyses of acetylcholinesterase (AChE) and its genetic variants in interaction with the anti‐Alzheimer drug Rivastigmine. Journal of Cellular Biochemistry 123:7, pages 1259-1277.
Crossref
Crossref
Mesut Işık. 2022. Hydrolases. Hydrolases.
Wantida Chaiyana, Suwannee Sriyab & Siriporn Okonogi. (2022) Enhancement of Cholinesterase Inhibition of Alpinia galanga (L.) Willd. Essential Oil by Microemulsions. Molecules 27:10, pages 3275.
Crossref
Crossref
S. Cunha, M. Swedrowska, Y. Bellahnid, Z. Xu, J.M. Sousa Lobo, Ben Forbes & A.C. Silva. (2022) Thermosensitive in situ hydrogels of rivastigmine-loaded lipid-based nanosystems for nose-to-brain delivery: characterisation, biocompatibility, and drug deposition studies. International Journal of Pharmaceutics 620, pages 121720.
Crossref
Crossref
Natália Chermont dos Santos Moreira, Jéssica Ellen Barbosa de Freitas Lima, Marcelo Fiori Marchiori, Ivone Carvalho & Elza Tiemi Sakamoto-Hojo. (2022) Neuroprotective Effects of Cholinesterase Inhibitors: Current Scenario in Therapies for Alzheimer’s Disease and Future Perspectives. Journal of Alzheimer's Disease Reports 6:1, pages 177-193.
Crossref
Crossref
Mehmet Ilkin Naharci, Betul Gulsum Yavuz Veizi, Bilal Katipoglu, Ece Akcan, Fatma Yoruk & Ilker Tasci. (2022) Massive Weight Loss From Rivastigmine Patch in an Older Patient. Journal of Clinical Psychopharmacology 42:2, pages 222-224.
Crossref
Crossref
Hasti Hadizadeh, Jose Flores, Eric Nunes, Talia Mayerson, Marc N. Potenza & Gustavo A. Angarita. (2022) Novel Pharmacological Agents for the Treatment of Cocaine Use Disorder. Current Behavioral Neuroscience Reports 9:1, pages 27-46.
Crossref
Crossref
Raafat A. Abdel-Aal, Ola A. Hussein, Reham G. Elsaady & Lobna A. Abdelzaher. (2022) Naproxen as a potential candidate for promoting rivastigmine anti-Alzheimer activity against aluminum chloride-prompted Alzheimer's-like disease in rats; neurogenesis and apoptosis modulation as a possible underlying mechanism. European Journal of Pharmacology 915, pages 174695.
Crossref
Crossref
Yasir Hasan Siddique, Falaq Naz, Rahul & Himanshi Varshney. (2022) Comparative study of rivastigmine and galantamine on the transgenic Drosophila model of Alzheimer's disease. Current Research in Pharmacology and Drug Discovery 3, pages 100120.
Crossref
Crossref
Gerhard N. Ransmayr. 2022. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
4207
4230
.
Prechiel A. Barredo, Marvin Jose F. Fernandez, Christopher E. Ambe & Mannix P. Balanay. (2021) Tau fibril with membrane lipids: Insight from computational modeling and simulations. PLOS ONE 16:10, pages e0258692.
Crossref
Crossref
Robert Morris, Gibret Umeukeje, Kun Bu & Feng Cheng. (2021) The Association Between Use of Rivastigmine and Pneumonia: Systematic Analysis of FDA Adverse Event Reporting System. Journal of Alzheimer's Disease 83:3, pages 1061-1071.
Crossref
Crossref
Sun-Wung Hsieh, Jui-Cheng Chen, Nai-Ching Chen, Kai-Ming Jhang, Wenfu Wang & Yuan-Han Yang. (2021) Real-world Evaluation of Tolerability, Safety and Efficacy of Rivastigmine Oral Solution in Patients with Mild to Moderate Alzheimer's Disease Dementia. Clinical Psychopharmacology and Neuroscience 19:3, pages 459-469.
Crossref
Crossref
Gabriella Marucci, Michela Buccioni, Diego Dal Ben, Catia Lambertucci, Rosaria Volpini & Francesco Amenta. (2021) Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease. Neuropharmacology 190, pages 108352.
Crossref
Crossref
Yuan-Ri Guo, Hui JinMinsang KimMyeong Bae ShinJu Hyeong LeeSungho MaengSeung-Yun ChaJeonghun LeeYoung Ho KohKee-Young KimSangkuk KangHyunwoo ParkJoo Won Suh. (2021)
Synergistic Neuroprotective Effects of Mature Silkworm and
Angelica gigas
Against Scopolamine-Induced Mild Cognitive Impairment in Mice and H
2
O
2
-Induced Cell Death in HT22 Mouse Hippocampal Neuronal Cells
. Journal of Medicinal Food 24:5, pages 505-516.
Crossref
Crossref
Natália F.F. Pirolla, Victor S. Batista, Flávia Pereira Dias Viegas, Vanessa Silva Gontijo, Caitlin R. McCarthy, Claudio Viegas & Nailton M. Nascimento-Júnior. (2021) Alzheimer's Disease: Related Targets, Synthesis of Available Drugs, Bioactive Compounds Under Development and Promising Results Obtained from Multi-target Approaches. Current Drug Targets 22:5, pages 505-538.
Crossref
Crossref
Jinsha Liu, Joey Paolo Ting, Shams Al-Azzam, Yun Ding & Sepideh Afshar. (2021) Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases. International Journal of Molecular Sciences 22:6, pages 2805.
Crossref
Crossref
Kevin Nguyen, Heidi Hoffman, Binu Chakkamparambil & George T Grossberg. (2021) Evaluation of rivastigmine in Alzheimer's disease. Neurodegenerative Disease Management 11:1, pages 35-48.
Crossref
Crossref
Mohamed Haider, Ibrahim Elsayed, Iman S. Ahmed & Ahmed R. Fares. (2021) In Situ-Forming Microparticles for Controlled Release of Rivastigmine: In Vitro Optimization and In Vivo Evaluation. Pharmaceuticals 14:1, pages 66.
Crossref
Crossref
Koula Doukani, Ammar Sidi Mohammed Selles & Hasna Bouhenni. 2021. Naturally Occurring Chemicals Against Alzheimer's Disease. Naturally Occurring Chemicals Against Alzheimer's Disease
225
241
.
Shahira M. Ezzat, Mohamed A. Salem, Nihal M. El Mahdy & Mai F. Ragab. 2021. Naturally Occurring Chemicals Against Alzheimer's Disease. Naturally Occurring Chemicals Against Alzheimer's Disease
93
108
.
Gerhard N. Ransmayr. 2020. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
1
24
.
Jeong Hyun Heo, Bo Hyun Eom, Hyung Won Ryu, Myung-Gyun Kang, Jong Eun Park, Doo-Young Kim, Jung-Hee Kim, Daeui Park, Sei-Ryang Oh & Hoon Kim. (2020) Acetylcholinesterase and butyrylcholinesterase inhibitory activities of khellactone coumarin derivatives isolated from Peucedanum japonicum Thurnberg. Scientific Reports 10:1.
Crossref
Crossref
Fathima Manaal Farouk, Luyi Ooi, Christine Shing Wei Law & Keng Yoon Yeong. (2020) Dual‐Target‐Directed Ligand Displaying Selective Butyrylcholinesterase Inhibitory and Neurite Promoting Activities as a Potential Therapeutic for Alzheimer's Disease. ChemistrySelect 5:36, pages 11229-11236.
Crossref
Crossref
Norwin Kubick, Patrick C. Henckell Flournoy, Ana-Maria Enciu, Gina Manda & Michel-Edwar Mickael. (2020) Drugs Modulating CD4+ T Cells Blood–Brain Barrier Interaction in Alzheimer’s Disease. Pharmaceutics 12:9, pages 880.
Crossref
Crossref
Valery M. Dembitsky, Lilya Dzhemileva, Tatyana Gloriozova & Vladimir D’yakonov. (2020) Natural and synthetic drugs used for the treatment of the dementia. Biochemical and Biophysical Research Communications 524:3, pages 772-783.
Crossref
Crossref
Gabriela Dumitrita Stanciu, Andrei Luca, Razvan Nicolae Rusu, Veronica Bild, Sorin Ioan Beschea Chiriac, Carmen Solcan, Walther Bild & Daniela Carmen Ababei. (2019) Alzheimer’s Disease Pharmacotherapy in Relation to Cholinergic System Involvement. Biomolecules 10:1, pages 40.
Crossref
Crossref
WenJun Yu, ShengJun An, TieMei Shao, HongJun Xu, HongXu Chen, JunDa Ning, YongJie Zhou & XiQing Chai. (2019) Active compounds of herbs ameliorate impaired cognition in APP/PS1 mouse model of Alzheimer’s disease. Aging 11:23, pages 11186-11201.
Crossref
Crossref
Francesco Mesiti, Daniel Chavarria, Alexandra Gaspar, Stefano Alcaro & Fernanda Borges. (2019) The chemistry toolbox of multitarget-directed ligands for Alzheimer's disease. European Journal of Medicinal Chemistry 181, pages 111572.
Crossref
Crossref
Ehab Mahran, Ibrahim El Gamal, Michael Keusgen & Gertrud E. Morlock. (2019) Effect-directed analysis by high-performance thin-layer chromatography for bioactive metabolites tracking in Primula veris flower and Primula boveana leaf extracts. Journal of Chromatography A 1605, pages 460371.
Crossref
Crossref
Gizem Tezel, Selin Seda Timur, İsmail Bozkurt, Ö. Faruk Türkoğlu, İpek Eroğlu, Emirhan Nemutlu, Levent Öner & Hakan Eroğlu. (2019) A Snapshot on the Current Status of Alzheimer’s Disease, Treatment Perspectives, <i>in-Vitro</i> and <i>in-Vivo</i> Research Studies and Future Opportunities. Chemical and Pharmaceutical Bulletin 67:10, pages 1030-1041.
Crossref
Crossref
M. Patel, C.D. Verrico & R. De La GarzaIIII. (2019) Rivastigmine does not alter cocaine-induced subjective effects or self-administration. Pharmacology Biochemistry and Behavior 185, pages 172758.
Crossref
Crossref
Eunkuk Park, Min Jeong Ryu, Nam Ki Kim, Mun Hyoung Bae, Youngha Seo, Jeonghyun Kim, Subin Yeo, Memoona Kanwal, Chun Whan Choi, Jun Young Heo & Seon-Yong Jeong. (2019) Synergistic Neuroprotective Effect of Schisandra chinensis and Ribes fasciculatum on Neuronal Cell Death and Scopolamine-Induced Cognitive Impairment in Rats. International Journal of Molecular Sciences 20:18, pages 4517.
Crossref
Crossref
Krešimir Baumann, Lorena Kordić, Marko Močibob, Goran Šinko & Srđanka Tomić. (2019) Synthesis and In Vitro Screening of Novel Heterocyclic β-d-Gluco- and β-d-Galactoconjugates as Butyrylcholinesterase Inhibitors. Molecules 24:15, pages 2833.
Crossref
Crossref
Kamlesh Sharma. (2019) Cholinesterase inhibitors as Alzheimer's therapeutics (Review). Molecular Medicine Reports.
Crossref
Crossref
Mridula Saxena & Ragini Dubey. (2019) Target Enzyme in Alzheimer’s Disease: Acetylcholinesterase Inhibitors. Current Topics in Medicinal Chemistry 19:4, pages 264-275.
Crossref
Crossref
Anthony Tabet & Chun Wang. (2018) Gels without Vapor Pressure: Soft, Nonaqueous, and Solvent‐Free Supramolecular Biomaterials for Prospective Parenteral Drug Delivery Applications. Advanced Healthcare Materials 8:6, pages 1800908.
Crossref
Crossref
Minky Son, Chanin Park, Shailima Rampogu, Amir Zeb & Keun Lee. (2019) Discovery of Novel Acetylcholinesterase Inhibitors as Potential Candidates for the Treatment of Alzheimer’s Disease. International Journal of Molecular Sciences 20:4, pages 1000.
Crossref
Crossref
PRA Heckman, A Blokland & A Sambeth. (2018) No interaction between rivastigmine and citalopram on memory and novelty processing in healthy human volunteers. Journal of Psychopharmacology 33:2, pages 210-218.
Crossref
Crossref
Anubhav Anand, Malti Arya, Gaurav Kaithwas, Gyanendra Singh & Shubhini A. Saraf. (2019) Sucrose stearate as a biosurfactant for development of rivastigmine containing nanostructured lipid carriers and assessment of its activity against dementia in C. elegans model. Journal of Drug Delivery Science and Technology 49, pages 219-226.
Crossref
Crossref
Yorley Duarte, André Fonseca, Margarita Gutiérrez, Francisco Adasme‐Carreño, Camila Muñoz‐Gutierrez, Jans Alzate‐Morales, Lourdes Santana, Eugenio Uriarte, Rocío Álvarez & Maria João Matos. (2019) Novel Coumarin‐Quinoline Hybrids: Design of Multitarget Compounds for Alzheimer's Disease. ChemistrySelect 4:2, pages 551-558.
Crossref
Crossref
Jacqueline Aparecida Takahashi, Denise Sande, Gesiane da Silva Lima, Marília Aparecida Fidelis e Moura & Matheus Thomaz Nogueira Silva Lima. 2019.
1
39
.
Tomomi Kiyota, Jatin Machhi, Yaman Lu, Bhagyalaxmi Dyavarshetty, Maryam Nemati, Gang Zhang, R. Lee Mosley, Harris A. Gelbard & Howard E. Gendelman. (2018) URMC-099 facilitates amyloid-β clearance in a murine model of Alzheimer’s disease. Journal of Neuroinflammation 15:1.
Crossref
Crossref
Mengnan Zhao & Christopher C Yang. (2018) Drug Repositioning to Accelerate Drug Development Using Social Media Data: Computational Study on Parkinson Disease. Journal of Medical Internet Research 20:10, pages e271.
Crossref
Crossref
Adel Penhasi & Mila Gomberg. (2018) A specific two-pulse release of rivastigmine using a modified time-controlled delivery system: A proof of concept case study. Journal of Drug Delivery Science and Technology 47, pages 404-410.
Crossref
Crossref
Miloš P. Stojiljković, Ranko Škrbić, Milan Jokanović, Vesna Kilibarda, Dubravko Bokonjić & Maja Vulović. (2018) Efficacy of antidotes and their combinations in the treatment of acute carbamate poisoning in rats. Toxicology 408, pages 113-124.
Crossref
Crossref
Dicson Sheeja Malar, Venkatesan Suryanarayanan, Mani Iyer Prasanth, Sanjeev Kumar Singh, Krishnaswamy Balamurugan & Kasi Pandima Devi. (2018) Vitexin inhibits Aβ25-35 induced toxicity in Neuro-2a cells by augmenting Nrf-2/HO-1 dependent antioxidant pathway and regulating lipid homeostasis by the activation of LXR-α. Toxicology in Vitro 50, pages 160-171.
Crossref
Crossref
Mengnan Zhao & Christopher C. Yang. (2018) Exploiting OHC Data with Tensor Decomposition for Off-Label Drug Use Detection. Exploiting OHC Data with Tensor Decomposition for Off-Label Drug Use Detection.
Asha Hiremathad, Karam Chand, Lori Tolayan, Rajeshwari, Rangappa S. Keri, A. Raquel Esteves, Sandra M. Cardoso, Sílvia Chaves & M. Amélia Santos. (2018) Hydroxypyridinone-benzofuran hybrids with potential protective roles for Alzheimer´s disease therapy. Journal of Inorganic Biochemistry 179, pages 82-96.
Crossref
Crossref
Dalia M.N. Abouhussein, Abeer Khattab, Noha A. Bayoumi, Ashgan F. Mahmoud & Tamer M. Sakr. (2018) Brain targeted rivastigmine mucoadhesive thermosensitive In situ gel: Optimization, in vitro evaluation, radiolabeling, in vivo pharmacokinetics and biodistribution. Journal of Drug Delivery Science and Technology 43, pages 129-140.
Crossref
Crossref
Gaetano Perrotta, Guillaume Bonnier, Djalel-Eddine Meskaldji, David Romascano, Ruslan Aydarkhanov, Alessandro Daducci, Samanta Simioni, Matthias Cavassini, Melanie Metral, François Lazeyras, Reto Meuli, Gunnar Krueger, Renaud A. Du Pasquier & Cristina Granziera. (2017) Rivastigmine decreases brain damage in HIV patients with mild cognitive deficits. Annals of Clinical and Translational Neurology 4:12, pages 915-920.
Crossref
Crossref
Eduardo Rojas-Gutierrez, Guadalupe Muñoz-Arenas, Samuel Treviño, Blanca Espinosa, Raúl Chavez, Karla Rojas, Gonzalo Flores, Alfonso Díaz & Jorge Guevara. (2017) Alzheimer's disease and metabolic syndrome: A link from oxidative stress and inflammation to neurodegeneration. Synapse 71:10, pages e21990.
Crossref
Crossref
Sainan Li, Chengyu Liu, Chunming Liu & Yuchi Zhang. (2017) Extraction and in vitro screening of potential acetylcholinesterase inhibitors from the leaves of Panax japonicus. Journal of Chromatography B 1061-1062, pages 139-145.
Crossref
Crossref
Galina F. Makhaeva, Vladimir B. Sokolov, Elena F. Shevtsova, Nadezhda V. Kovaleva, Sofya V. Lushchekina, Natalia P. Boltneva, Elena V. Rudakova, Alexey Yu. Aksinenko, Pavel N. Shevtsov, Margarita E. Neganova, Ludmila G. Dubova & Sergey O. Bachurin. (2017) Focused design of polypharmacophoric neuroprotective compounds: Conjugates of γ-carbolines with carbazole derivatives and tetrahydrocarbazole. Pure and Applied Chemistry 89:8, pages 1167-1184.
Crossref
Crossref
Tzu-Hua Chen, Mei-Chuan Chou, Chiou-Lian Lai, Shyh-Jong Wu, Chia-Ling Hsu & Yuan-Han Yang. (2017) Factors affecting therapeutic response to Rivastigmine in Alzheimer's disease patients in Taiwan. The Kaohsiung Journal of Medical Sciences 33:6, pages 277-283.
Crossref
Crossref
Moon K. Song, David S. Bischoff, Albert M. Song, Koichi Uyemura & Dean T. Yamaguchi. (2017) Metabolic relationship between diabetes and Alzheimer's Disease affected by Cyclo(His-Pro) plus zinc treatment. BBA Clinical 7, pages 41-54.
Crossref
Crossref
Meha Fatima Aftab, Shabbir Khan Afridi, Uzma Rasool Mughal, Aneela Karim, Darakhshan Jabeen Haleem, Nurul Kabir, Khalid M. Khan, Rahman M. Hafizur & Rizwana S. Waraich. (2017) New isatin derivative inhibits neurodegeneration by restoring insulin signaling in brain. Journal of Chemical Neuroanatomy 81, pages 1-9.
Crossref
Crossref
Keng Yoon Yeong, Wai-Lam Liew, Vikneswaran Murugaiyah, Chee Wei Ang, Hasnah Osman & Soo Choon Tan. (2017) Ethyl nitrobenzoate: A novel scaffold for cholinesterase inhibition. Bioorganic Chemistry 70, pages 27-33.
Crossref
Crossref
Pia Basaure, Fiona Peris-Sampedro, Maria Cabré, Ingrid Reverte & Maria Teresa Colomina. (2017) Two cholinesterase inhibitors trigger dissimilar effects on behavior and body weight in C57BL/6 mice: The case of chlorpyrifos and rivastigmine. Behavioural Brain Research 318, pages 1-11.
Crossref
Crossref
Gilbert Lefèvre, Francesca Callegari, Sandro Gsteiger & Yuan Xiong. (2016) Effects of Renal Impairment on Steady-State Plasma Concentrations of Rivastigmine: A Population Pharmacokinetic Analysis of Capsule and Patch Formulations in Patients with Alzheimer’s Disease. Drugs & Aging 33:10, pages 725-736.
Crossref
Crossref
Olivier Beauchet, John Barden, Teresa Liu-Ambrose, Victoria L. Chester, Cedric Annweiler, Tony Szturm, Sébastien Grenier, Guillaume Léonard, Louis Bherer & Gilles Allali. (2016) Anti-Dementia Drugs, Gait Performance and Mental Imagery of Gait: A Non-Randomized Open-Label Trial. Drugs & Aging 33:9, pages 665-673.
Crossref
Crossref
Bo-Lin Ho, Yi-Hui Kao, Mei-Chuan Chou & Yuan-Han Yang. (2016) Cerebral White Matter Changes on Therapeutic Response to Rivastigmine in Alzheimer’s Disease. Journal of Alzheimer's Disease 54:1, pages 351-357.
Crossref
Crossref
Sachiko Nozaki, Masayuki Yamaguchi & Gilbert Lefèvre. (2016) Pharmacokinetic Modeling to Simulate the Concentration-Time Profiles After Dermal Application of Rivastigmine Patch. Journal of Pharmaceutical Sciences 105:7, pages 2213-2221.
Crossref
Crossref
Rabya Munawar, Nousheen Mushtaq, Sadia Arif, Ahsaan Ahmed, Shamim Akhtar, Sumaira Ansari, Sadia Meer, Zafar S. Saify & Muhammad Arif. (2015) Synthesis of 9-Aminoacridine Derivatives as Anti-Alzheimer Agents. American Journal of Alzheimer's Disease & Other Dementiasr 31:3, pages 263-269.
Crossref
Crossref
Abdul Hameed, Syeda T. Zehra, Syed J. A. Shah, Khalid M. Khan, Rima D. Alharthy, Norbert Furtmann, Jürgen Bajorath, Muhammad N. Tahir & Jamshed Iqbal. (2015)
Syntheses, Cholinesterases Inhibition, and Molecular Docking Studies of Pyrido[2,3-
b
]pyrazine Derivatives
. Chemical Biology & Drug Design 86:5, pages 1115-1120.
Crossref
Crossref
Kosuke Matsuzono, Kota Sato, Syoichiro Kono, Nozomi Hishikawa, Yasuyuki Ohta, Toru Yamashita, Kentaro Deguchi, Yumiko Nakano & Koji Abe. (2015) Clinical Benefits of Rivastigmine in the Real World Dementia Clinics of the Okayama Rivastigmine Study (ORS). Journal of Alzheimer's Disease 48:3, pages 757-763.
Crossref
Crossref
Sagar H. Barage & Kailas D. Sonawane. (2015) Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease. Neuropeptides 52, pages 1-18.
Crossref
Crossref
Xian-hui Dong, Jiang-tao Bai, Wei-na Kong, Xiao-ping He, Peng Yan, Tie-mei Shao, Wen-guo Yu, Xi-qing Chai, Yan-hua Wu & Cong LIu. (2015) Effective components of Chinese herbs reduce central nervous system function decline induced by iron overload. Neural Regeneration Research 10:5, pages 778.
Crossref
Crossref
Xiaodan Guo, Wei Jiang, Chenjing Li, Zhiyuan Zhu & Xu Shen. (2015) Aβ regulation-based multitarget strategy for drug discovery against Alzheimer’s disease. Reviews in the Neurosciences 26:1.
Crossref
Crossref
Zhijie Li, Qing Tong, Huifang Xu, Li Hu, Rong Zhao, Fang Zhou, Wei Pan & Li Zhou. (2015)
Therapeutic Effects of TianDiJingWan on the A
β
25–35
-Induced Alzheimer’s Disease Model Rats
. Evidence-Based Complementary and Alternative Medicine 2015, pages 1-9.
Crossref
Crossref
O. Beauchet, C. P. Launay, G. Allali & C. Annweiler. (2014) Changes in Gait Variability with Anti-dementia Drugs: A Systematic Review and Meta-analysis. CNS Drugs 28:6, pages 513-518.
Crossref
Crossref
Olivier Beauchet, Cyrille P. Launay, Gilles Allali, François R. Herrmann & Cedric Annweiler. (2014) Gait Changes with Anti-Dementia Drugs: A Prospective, Open-Label Study Combining Single and Dual Task Assessments in Patients with Alzheimer’s Disease. Drugs & Aging 31:5, pages 363-372.
Crossref
Crossref
Zhaoxi Zheng, Yabin Tang, Haoyu Lv, Jianrong Xu, Hengyi Zhao, Qiong Xie, Zhuibai Qiu, Hongzhuan Chen & Hao Wang. (2014) Determination of Meserine, a new candidate for Alzheimer’s disease in mice brain by liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic and tissue distribution study. Analytical and Bioanalytical Chemistry 406:14, pages 3451-3458.
Crossref
Crossref
Yang Su, Qiuhong Wang, Changfu Wang, Kelvin Chan, Yanping Sun & Haixue Kuang. (2014) The treatment of Alzheimer's disease using Chinese Medicinal Plants: From disease models to potential clinical applications. Journal of Ethnopharmacology 152:3, pages 403-423.
Crossref
Crossref
Gianfranco Spalletta, Carlo Caltagirone, Alessandro Padovani, Sandro Sorbi, Mahmood Attar, Delia Colombo & Luca Cravello. (2014) Cognitive and Affective Changes in Mild to Moderate Alzheimer’s Disease Patients Undergoing Switch of Cholinesterase Inhibitors: A 6-Month Observational Study. PLoS ONE 9:2, pages e89216.
Crossref
Crossref
Vageesh Revadigar, Raza Murad Ghalib, Vikneswaran Murugaiyah, Mohamed A. Embaby, Ali Jawad, Sayed Hasan Mehdi, Rokiah Hashim & Othman Sulaiman. 2014. Drug Design and Discovery in Alzheimer's Disease. Drug Design and Discovery in Alzheimer's Disease
142
198
.
Olivier Beauchet, Cyrille P Launay, Gazan Allali, Gilles Watfa, Karim Gallouj, François R Herrmann & Cédric Annweiler. (2013) Anti-dementia drugs and changes in gait: a pre-post quasi-experimental pilot study. BMC Neurology 13:1.
Crossref
Crossref
Lawrence S. Honig & Clara D. Boyd. (2013) Treatment of Alzheimer’s Disease: Current Management and Experimental Therapeutics. Current Translational Geriatrics and Experimental Gerontology Reports 2:3, pages 174-181.
Crossref
Crossref
Ina Tesseur, Anna A. Pimenova, Adrian C. Lo, Marta Ciesielska, Stefan F. Lichtenthaler, Joris H. De Maeyer, Jan A.J. Schuurkes, Rudi D'Hooge & Bart De Strooper. (2013) Chronic 5-HT4 receptor activation decreases Aβ production and deposition in hAPP/PS1 mice. Neurobiology of Aging 34:7, pages 1779-1789.
Crossref
Crossref
Anthony J. Veloso, Devjani Dhar, Ari M. Chow, Biao Zhang, Derek W. F. Tang, Hashwin V. S. Ganesh, Svetlana Mikhaylichenko, Ian R. Brown & Kagan Kerman. (2012)
sym
-Triazines for Directed Multitarget Modulation of Cholinesterases and Amyloid-β in Alzheimer’s Disease
. ACS Chemical Neuroscience 4:2, pages 339-349.
Crossref
Crossref
Nirmal Sonali, Manjari Tripathi, Rajesh Sagar, Thirumurthy Velpandian & Vivekanandhan Subbiah. (2012) Clinical Effectiveness of Rivastigmine Monotherapy and Combination Therapy in Alzheimer's Patients. CNS Neuroscience & Therapeutics 19:2, pages 91-97.
Crossref
Crossref
Johannah Uriri-Glover, Marianne McCarthy & Evelyn Cesarotti. (2012) Solving the puzzle of Alzheimer disease. The Nurse Practitioner 37:9, pages 20-27.
Crossref
Crossref
A. Hornick, A. Lieb, N.P. Vo, J.M. Rollinger, H. Stuppner & H. Prast. (2011) The coumarin scopoletin potentiates acetylcholine release from synaptosomes, amplifies hippocampal long-term potentiation and ameliorates anticholinergic- and age-impaired memory. Neuroscience 197, pages 280-292.
Crossref
Crossref
Fadi Massoud & Gabriel C Léger. (2011) Pharmacological Treatment of Alzheimer Disease. The Canadian Journal of Psychiatry 56:10, pages 579-588.
Crossref
Crossref
Fei Shen, Jacqueline A.M. Smith, Ray Chang, David L. Bourdet, Pamela R. Tsuruda, Glenmar P. Obedencio & David T. Beattie. (2011) 5-HT4 receptor agonist mediated enhancement of cognitive function in vivo and amyloid precursor protein processing in vitro: A pharmacodynamic and pharmacokinetic assessment. Neuropharmacology 61:1-2, pages 69-79.
Crossref
Crossref
Fadi Massoud, Julie Eve Desmarais & Serge Gauthier. (2010) Switching cholinesterase inhibitors in older adults with dementia. International Psychogeriatrics 23:3, pages 372-378.
Crossref
Crossref
Guillaume Bastiat, François Plourde, Aude Motulsky, Alexandra Furtos, Yvan Dumont, Rémi Quirion, Gregor Fuhrmann & Jean-Christophe Leroux. (2010) Tyrosine-based rivastigmine-loaded organogels in the treatment of Alzheimer’s disease. Biomaterials 31:23, pages 6031-6038.
Crossref
Crossref
Jean Marc Miezan Ezoulin, Bi-yun Shao, Zheng Xia, Qiong Xie, Juan Li, Yong-yao Cui, Hao Wang, Chang-zhi Dong, Yan-xing Zhao, France Massicot, Zhui-bai Qiu, Françoise Heymans & Hong-zhuan Chen. (2009) Novel piperazine derivative PMS1339 exhibits tri-functional properties and cognitive improvement in mice. The International Journal of Neuropsychopharmacology 12:10, pages 1409.
Crossref
Crossref
Marco Calabria, Cristina Geroldi, Giulia Lussignoli, Federica Sabbatini & Orazio Zanetti. (2009) Efficacy of acetyl-cholinesterase-inhibitor (ACHEI) treatment in Alzheimer's disease: A 21-month follow-up “real world” study. Archives of Gerontology and Geriatrics 49:1, pages e6-e11.
Crossref
Crossref
Juan Li, Jinjia Hu, Biyun Shao, Wei Zhou, Yongyao Cui, Changzhi Dong, Jean-Marc Miezan Ezoulin, Xu Zhu, Wenlong Ding, Françoise Heymans & Hongzhuan Chen. (2009) Protection of PMS777, a New AChE Inhibitor with PAF Antagonism, Against Amyloid-β-Induced Neuronal Apoptosis and Neuroinflammation. Cellular and Molecular Neurobiology 29:4, pages 589-595.
Crossref
Crossref
E. G. Visch-Brink, W. Rhee-Temme, T. Rietveld, J. W. M. Krulder, F. Harskamp & T. J. M. Cammen. (2009) Improvement of spontaneous speech in early stage Alzheimer’s disease with rivastigmine. The Journal of Nutrition, Health and Aging 13:1, pages 34-38.
Crossref
Crossref
Helmut Niederhofer. (2008) Acetylcholinesterase Inhibitors May Improve Efficacy and Reduce Adverse Effects of Tricyclic Antidepressants for Depression. Drugs & Aging 25:8, pages 715.
Crossref
Crossref
Yasir Hasan Siddique, Falaq Naz, Rahul -Himanshi Varshney. (2022) Comparative Study of Rivastigmine and Galantamine on the Transgenic Drosophila Model of Alzheimer's Disease. SSRN Electronic Journal.
Crossref
Crossref